Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9056 Bendamustine Vivimusta 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2022 Jul 11, 2023 In Use
Q5130 Pegfilgrastim-pbbk Fylnetra 0.5mg Ancillary Therapy Immunostimulant Granulocyte colony stimulating factor No 2022 Mar 17, 2023 In Use
Q5126 Bevacizumab-maly Alymsys 10mg Immunotherapy Monoclonal Antibody VEGF No 2022 Nov 28, 2022 In Use
J9296 Pemetrexed (Accord) Pemetrexed (Accord) 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Mar 17, 2023 In Use
J9051 Bortezomib (Maia) Bortezomib 0.1mg Chemotherapy Proteasome Inhibitor 26S Yes 2022 Aug 28, 2023 In Use
J9274 Tebentafusp-tebn Kimmtrak 1mcg Immunotherapy T Cell Receptor (TCR) HLA-A*02:01 No 2022 Sep 27, 2022 In Use
J9298 Nivolumab & relatlimab-rmbw Opdualag 3mg/1mg Immunotherapy Checkpoint Inhibitor, Monoclonal Antibody PD-1, LAG3 No 2022 Sep 27, 2022 In Use
Pacritinib Vonjo 100mg Chemotherapy Tyrosine Kinase Inhibitor JAK2, FLT3 Yes 2022 In Use
J9350 Mosunetuzumab-axgb Lunsumio 1mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2022 Jul 11, 2023 In Use
C9095 Tebentafusp-tebn Kimmtrak 1mcg Immunotherapy T Cell Receptor (TCR) HLA-A*02:01 No 2022 Mar 25, 2022 Sep 27, 2022 No Longer Used
C9087 Cyclophosphamide (Auromedics) Cyclophosphamide 10mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2021 Jan 26, 2022 Mar 25, 2022 In Use
J1932 Lanreotide (Cipla) Lanreotide Acetate 1mg Hormonal Therapy Somatostatin Analog No 2021 Sep 27, 2022 In Use
C9083 Amivantamab-vmjw Rybrevant 10mg Immunotherapy Monoclonal Antibody EGFR,MET No 2021 Sep 27, 2021 Jan 26, 2022 No Longer Used
J1952 Leuprolide Mesylate Camcevi 1mg Hormonal Therapy GnRH Agonist No 2021 Jan 26, 2022 In Use
J9061 Amivantamab Rybrevant 2mg Immunotherapy Monoclonal Antibody EGFR, MET No 2021 Jan 26, 2022 In Use
C9076 Lisocabtagene maraleucel Breyanzi Immunotherapy CAR-T CD19 No 2021 Jul 23, 2021 Sep 27, 2021 No Longer Used
Q2054 Lisocabtagene maraleucel Breyanzi Immunotherapy CAR-T CD19 No 2021 Sep 27, 2021 In Use
J9021 Asparaginase Erwinia Chrysanthemi (recombinant)-rywn Rylaze 0.1mg Chemotherapy Miscellaneous Agent Enzyme No 2021 Jan 26, 2022 In Use
NA Dostarlimab Jemperli 50mg Immunotherapy Checkpoint Inhibitor PD-1 Yes 2021 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
Maribavir Livtencity 200mg Ancillary Therapy Miscellaneous Agent CMV Antiviral Yes 2021 In Use
J9247 Melphalan flufenamide Pepaxto 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2021 Sep 27, 2021 In Use
C9081 Idecabtagene vicleucel Abecma up to 460000000 Immunotherapy CAR-T BCMA No 2021 Sep 27, 2021 Jan 26, 2022 No Longer Used
J9272 Dostarlimab-gxly Jemperli 10mg Immunotherapy Checkpoint Inhibitor PD-1 No 2021 Jan 26, 2022 In Use
J9353 Margetuximab-cmkb Margenza 5mg Immunotherapy Monoclonal Antibody HER2 No 2021 Jul 23, 2021 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.